Valuation: Entrada Therapeutics, Inc.

Market Cap 243M 212M 200M 182M 341M 23.35B 342M 2.4B 926M 11.87B 914M 894M 38.2B P/E 2026 *
-1.68x
P/E 2027 * -1.87x
Enterprise Value 213M 186M 176M 159M 299M 20.46B 300M 2.1B 812M 10.4B 801M 783M 33.48B EV / Sales 2026 *
17.5x
EV / Sales 2027 * -1.56x
Free-Float
85.81%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week-0.74%
Current month-4.26%
1 month-7.15%
3 months-4.80%
6 months-43.18%
Current year-34.34%
1 week 6.6
Extreme 6.6
7.07
1 month 6.29
Extreme 6.29
7.76
Current year 5.63
Extreme 5.63
16.45
1 year 5.08
Extreme 5.08
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 2017-07-31
Director of Finance/CFO 47 2020-10-31
President 56 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2017-07-31
Chairman 45 2020-11-30
Director/Board Member 67 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
9/3/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-0.74%+21.62%-52.86% 242M
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.75%+1.41%+35.66%+182.75% 27.51B
Weighted average by Cap. -0.47%+1.44%+36.49%+147.80%

Financials

2026 *2027 *
Net sales 12.17M 10.61M 10.02M 9.1M 17.04M 1.17B 17.11M 120M 46.3M 594M 45.7M 44.69M 1.91B 22.86M 19.93M 18.82M 17.09M 32.02M 2.19B 32.16M 225M 87M 1.12B 85.87M 83.97M 3.59B
Net income -174M -152M -144M -130M -244M -16.73B -245M -1.72B -664M -8.51B -655M -640M -27.37B -184M -161M -152M -138M -258M -17.7B -259M -1.82B -702M -9B -693M -677M -28.95B
Net Debt -30.12M -26.27M -24.8M -22.52M -42.2M -2.89B -42.37M -297M -115M -1.47B -113M -111M -4.73B -279M -243M -230M -209M -391M -26.78B -393M -2.75B -1.06B -13.61B -1.05B -1.03B -43.81B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
26-09-18 US$6.750 -2.17% 354,430
26-09-17 US$6.900 +0.15% 297,364
26-09-16 US$6.890 +0.15% 249,217
26-09-15 US$6.880 -2.41% 247,765
26-09-14 US$7.050 +3.68% 336,096
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.750USD
Average target price
19.00USD
Spread / Average Target
+181.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!